CM Life Sciences II To Combine With Proteomics SomaLogic In Latest SPAC Deal
The SPAC deal between CM Life Sciences II and SomaLogic is valued at $1.25bn.
You may also be interested in...
Vicarious Surgical, whose medical robot received US FDA breakthrough designation, announced it will merge with D8 Holdings Corp. The deal is expected to garner up to $460m.
EcoR1 and Casdin/Corvex took their second and third special purpose acquisition corporations public. Also, Ionis sold notes to buy back older notes and fund operations as it cut 70% of Akcea’s staff. In venture capital, ValenzaBio raised $70m and RA boosted Metagenomi’s series A to $75m.
LumiraDX secured $400m in new debt financing and will use all proceeds to fund growth.